Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and increase weight loss efficacy in combination with...
Saved in:
Main Authors: | Nina Sonne (Author), Morten A. Karsdal (Author), Kim Henriksen (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
by: K.V. Andreassen, et al.
Published: (2021) -
Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons
by: Lavinia Boccia, et al.
Published: (2022) -
Salmon Calcitonin Exerts an Antidepressant Effect by Activating Amylin Receptors
by: Jian Jiang, et al.
Published: (2022) -
Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
by: Aqfan Jamaluddin, et al.
Published: (2022) -
Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
by: Eric R Ocheretyaner, et al.
Published: (2022)